These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 4577009)
1. Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437). Fellin R; Fedele D; Bagnariol G; Pagnan A; Crepaldi G Atherosclerosis; 1973; 17(3):383-8. PubMed ID: 4577009 [No Abstract] [Full Text] [Related]
2. Comparative study of several hypolipidemic agents related to clofibrate. Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878 [No Abstract] [Full Text] [Related]
3. Comparative hypolipidaemic effectiveness of gum guggulu (Commiphora mukul) fraction 'A', ethyl-P-chlorophenoxyisobutyrate and Ciba-13437-Su. Malhotra SC; Ahuja MM Indian J Med Res; 1971 Oct; 59(10):1621-32. PubMed ID: 5159000 [No Abstract] [Full Text] [Related]
4. Effects of CH 13.437 in different types of hyperlipidemia. Harvengt C Arch Int Pharmacodyn Ther; 1972 Apr; 196():Suppl 196:298+. PubMed ID: 4559547 [No Abstract] [Full Text] [Related]
5. Treatment of essential hyperlipidaemia. Fredrickson DS; Levy RI Lancet; 1970 Jan; 1(7639):191-2. PubMed ID: 4189261 [No Abstract] [Full Text] [Related]
6. Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients. Weiss P; Dujovne CA; Margolis S; Lasagna L; Bianchine JR Clin Pharmacol Ther; 1970; 11(1):90-6. PubMed ID: 4903694 [No Abstract] [Full Text] [Related]
8. A comparative study of a new drug MK 185 with clofibrate in the treatment of hyperlipidaemias. Jepson EM; Small E; Grayson MF; Bance G; Billimoria JD Atherosclerosis; 1972; 16(1):9-14. PubMed ID: 4341723 [No Abstract] [Full Text] [Related]
9. Reduction of serum lipids in familial hyperlipidemias by a tetralin derivative. Oriente P; Motolese M; Cerqua R; Mancini M Int Z Klin Pharmakol Ther Toxikol; 1969 Oct; 2(4):348-53. PubMed ID: 4903988 [No Abstract] [Full Text] [Related]
10. Effect of a hypolipidaemic drug (CH 13,437) on plasma and tissue lipids, and on the intravenous fat tolerance in man. Boberg J; Carlson LA; Fröberg SO; Orö L Atherosclerosis; 1970; 11(2):353-60. PubMed ID: 4353910 [No Abstract] [Full Text] [Related]
11. The hypolipidemic effect of SU-13,437 in rats with natural endogenous hypertriglyceridemia. Lenz PH; Fleischman AI Lipids; 1971 Nov; 6(11):783-6. PubMed ID: 5127473 [No Abstract] [Full Text] [Related]
12. A comparative study of different electrophoretic techniques for classification of hereditary hyperlipoproteinaemias. Heiberg A Clin Genet; 1973; 4(5):450-60. PubMed ID: 4127396 [No Abstract] [Full Text] [Related]
13. [Therapeutic effect of Ciba 13437-Su in 40 patients with familial essential hyperlipemia]. Schönbeck M; Forster G; Hirzel H; Jakab T; Rosenmund H Dtsch Med Wochenschr; 1970 Aug; 95(35):1761-8. PubMed ID: 5451984 [No Abstract] [Full Text] [Related]
14. Treatment of hypertriglyceridemia with tibric acid and clofibrate. Cross-over studies, effects on lipoproteins and absence of post-drug rebound. Smith FR; Noble RP; Goodman DS Atherosclerosis; 1978 Mar; 29(3):345-54. PubMed ID: 666884 [No Abstract] [Full Text] [Related]
19. [Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia]. Arteaga A; Foradori A; Eyzaguirre J; Lira P; Vasquez A; Soto S; Alliende ME; Guzman L Rev Med Chil; 1970 Oct; 98(10):689-94. PubMed ID: 4927028 [No Abstract] [Full Text] [Related]
20. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia. Hutchison JC; Wilkinson WH Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481 [No Abstract] [Full Text] [Related] [Next] [New Search]